(Q43267738)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Gulnara Patrícia Borja-Cabrera

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

Clarisa Beatriz Palatnik-de-Sousa

9 February 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

author name string

F N Santos

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F B Santos

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Fernando Antonio de A Trivellato

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Jarbas Kiyoshi A Kawasaki

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Andreia Cerqueira Costa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Tatiana Castro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

F S Nogueira

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M A B Moreira

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M C R Luvizotto

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

M Palatnik

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

language of work or name

English

0 references

publication date

1 October 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

597-603

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19800443%20AND%20SRC:MED&resulttype=core&format=json

Infectiousness in a cohort of brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission

9 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

inferred from DOI database lookup

7 January 2021

based on heuristic

Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Phase I and II open clinical trials of a vaccine against Leishmania chagasi Infections in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Immunogenicity assay of the Leishmune vaccine against canine visceral leishmaniasis in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Chemotherapy of canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

The fucose-mannose ligand-ELISA in the diagnosis and prognosis of canine visceral leishmaniasis in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Short report: occurrence of Leishmania donovani DNA in donated blood from seroreactive Brazilian blood donors

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

inferred from DOI database lookup

7 January 2021

based on heuristic

Cytology of cutaneous lesions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Amplification of kinetoplast DNA as a tool in the detection and diagnosis of Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Acylated and deacylated saponins of Quillaja saponaria mixture as adjuvants for the FML-vaccine against visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Protective vaccination against murine visceral leishmaniasis using aldehyde-containing Quillaja saponaria sapogenins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Epidemiology of canine visceral leishmaniosis in the endemic area of Montes Claros Municipality, Minas Gerais State, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Polymorphism of Slc11a1 (Nramp1) Gene and Canine Leishmaniasis in a Case-Control Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Slc11a1 (formerly Nramp1) and susceptibility to canine visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Canine visceral leishmaniasis, United States and Canada, 2000-2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Comparison of different tissue sampling for PCR-based diagnosis and follow-up of canine visceral leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Evaluation of a specific immunochemotherapy for the treatment of canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Detection of Leishmania infantum by PCR, serology and cellular immune response in a cohort study of Brazilian dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Activity of amphotericin B in lipid emulsion in the initial treatment of canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Immunotherapy, immunochemotherapy and chemotherapy for American cutaneous leishmaniasis treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071

Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.09.071